Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07544628 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 1 Study of Navlimetostat Tablet Formulations

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 months later Aug 31, 2026 → Nov 2, 2026
See other at-risk trials from Bristol-Myers Squibb

Record History

  1. Primary completion pushed from Aug 31, 2026 to Nov 2, 2026 Completion date: Oct 15, 2026 to Nov 2, 2026 · Eligibility criteria expanded, about 6 words · Secondary endpoints: details revised at 2 of 5 entries Show 3 more changesShow less
    • Completion date: Oct 15, 2026 to Nov 2, 2026
    • Eligibility criteria expanded, about 6 words
    • Secondary endpoints: details revised at 2 of 5 entries
  2. Study sites: 3 to 4v3
  3. Recruitment opened Trial sites expanded: 0 → 3 locations · Start date changed from estimate of Apr 30, 2026 to Apr 27, 2026v2 Show 2 more changesShow less
    • Trial sites expanded: 0 → 3 locations
    • Start date changed from estimate of Apr 30, 2026 to Apr 27, 2026
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study aims to compare the PK of Navlimetostat after administration of a wet-granulation tablet versus the dry-granulation tablet formulation in healthy adult female
Trial Details
NCT Number NCT07544628
Lead Sponsor Bristol-Myers Squibb
Conditions Healthy Participants
Enrollment 64 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov